Gilead Sciences' experimental drug sofosbuvir achieved the primary goal of two late-stage trials involving treatment-naive patients with chronic hepatitis C virus. The firm plans to use the results to support a marketing application in the U.S. this year.
Gilead's hepatitis C drug sofosbuvir hits main goal in trials
SmartBrief Job Listings for Health Care
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|